Showing 2181-2190 of 2657 results for "".
- SAV-IOL to Showcase IOL Technology at ESCRS 2022https://modernod.com/news/sav-iol-to-showcase-new-iol-technology-at-escrs-2022/2481038/After nearly 3 years of virtual congresses and canceled tradeshows worldwide, SAV-IOL announced it will be exhibiting at this year’s ESCRS event in Milan, Italy, September 16-19 at stand B14 at MiCo Convention Centre. SAV-IOL invites all participants to come check out their E
- Show Organizers Announce Reimagined Floor Plan for Vision Expo East 2023https://modernod.com/news/show-organizers-announce-reimagined-floor-plan-for-vision-expo-east-2023/2481037/The Vision Council and RX, co-organizers of Vision Expo, shared plans for a reimagined show floor layout that will debut at Vision Expo East 2023, taking place March 16–19 at the Javits Center in New York City. The new layout will feature all of Vision Expo’s Show Fl
- CooperVision MiSight 1 Day Officially Launches in Chinahttps://modernod.com/news/coopervision-misight-1-day-officially-launches-in-china/2481026/CooperVision and EssilorLuxottica have officially launched MiSight 1 day contact lenses in China, marking its availability in the world’s largest country for myopia management. It is the first product of any type that has an indication from the Chinese National Medical Products Adminis
- Research to Prevent Blindness and the American Academy of Ophthalmology Award New Research Grants to Improve Eye Carehttps://modernod.com/news/research-to-prevent-blindness-and-the-american-academy-of-ophthalmology-award-new-research-grants-to-improve-eye-care/2481025/The American Academy of Ophthalmology and Research to Prevent Blindness (RPB) announced the 2022 recipients of the RPB/AAO Award for IRIS Registry Research. The researchers will use the IRIS Registry—the nation’s first and largest comprehensive eye disease clinical registry—to c
- Ocuphire Extends US Patent Protection for Drug Candidate Nyxol for Reversal of Mydriasis by 5 More Years Into 2039https://modernod.com/news/ocuphire-extends-us-patent-protection-for-drug-candidate-nyxol-for-reversal-of-mydriasis-by-5-more-years-into-2039/2481011/Ocuphire Pharma announced the issuance of a new U.S. Patent (No. 11,400,077), which provides added intellectual property protection for the company’s late-stage product candidate, Nyxol (phentolamine mesylate), with claims directed to methods for treating mydriasis using phentolamine m
- AbbVie and iSTAR Medical Announce Strategic Alliancehttps://modernod.com/news/abbvie-and-istar-medical-announce-strategic-alliance/2480980/AbbVie and iSTAR Medical announced a strategic transaction to further develop and commercialize iSTAR Medical’s MINIject device, a minimally invasive glaucoma surgical (MIGS) device for patients with glaucoma. The deal gives AbbVie the exclusive right to acquire iST
- Avista Therapeutics Partners with Roche to Develop Next-Generation AAV Gene Therapy Vectors for Ocular Diseaseshttps://modernod.com/news/avista-therapeutics-partners-with-roche-to-develop-next-generation-aav-gene-therapy-vectors-for-ocular-diseases/2480977/Avista Therapeutics, which recently launched as a spinout of the University of Pittsburgh Medical Center (UPMC), announced a partnership with Roche to develop novel AAV gene therapy vectors for the eyes. The partnership aims to apply Avista’s single-cell adeno-associated
- Frontera Therapeutics Completes $160 Million Series B Financing to Fund Clinical Development and Manufacturing Capabilitieshttps://modernod.com/news/frontera-therapeutics-completes-160-million-series-b-financing-to-fund-clinical-development-and-manufacturing-capabilities/2480975/Frontera Therapeutics announced successful completion of a $160 million Series B funding round. In addition, Frontera announced that the FDA has accepted the company’s investigational new drug (IND) application to initiate a first-in-human clinical trial of FT
- Prevent Blindness Holds 11th Annual Focus on Eye Health National Summit as Two-Day Virtual Eventhttps://modernod.com/news/prevent-blindness-holds-11th-annual-focus-on-eye-health-national-summit-as-two-day-virtual-event/2480966/Preventg Blindness held the 11th annual Prevent Blindness Focus on Eye Health National Summit as a virtual event on July 13-14, 2022. This year’s Summit engaged more than 840 registered attendees, and included a variety of presentations related to the theme "Eye-conic Ap
- Iveric Bio and DelSiTech Enter Exclusive Agreement for Development of Sustained Release Zimurahttps://modernod.com/news/iveric-bio-and-delsitech-enter-exclusive-agreement-for-development-of-sustained-release-zimura/2480948/Iveric bio and DelSiTech announced an exclusive global license agreement providing Iveric Bio with the right to develop and commercialize new formulations of Zimura (avacincaptad pegol) using DelSiTech’s silica-based sustained release technology. Under the terms of the l